---
ID: P91
Title: Genomic Variant Actionability Arbiter
Registry: CLAI-OS Precision Engine (P-series)
License: Open documentation release (prompt body withheld for validation)
Version: 1.0.0
Author: Dr. Christabel Odeta — SAVANT FRAMEWORK · CLAI-OS · AEGIS-GLOBAL
Last Updated: 2026-10-12
---

# P91: Genomic Variant Actionability Arbiter

## Abstract

The accumulation of clinically unresolved genomic findings delays treatment, obscures hereditary risk, propagates therapeutic mismatch, and produces inconsistent interpretation between institutions. P91 is a real-time molecular adjudication architecture that transforms raw variant data into evidence-ranked therapeutic, prognostic, hereditary, and pharmacologic action pathways across somatic oncology, constitutional genetics, pharmacogenomics, and hematologic precision medicine.

> Prompt body: WITHHELD. This is an open documentation release — abstract, methodology, and merits — published so the design can be examined and validated.

## Methodology

**Design objectives**

- Variant ingestion and normalization across WGS, WES, targeted panels, RNA-seq, and liquid biopsy, with GRCh38 alignment, quality thresholds, and automatic orthogonal validation triggers for low-confidence variants.
- Actionability classification integrating ACMG/AMP, AMP/ASCO/CAP, ESCAT, and OncoKB tiers, with dynamic confidence recalculation from functional assay evidence, segregation studies, population frequencies, and real-world outcomes.
- Pharmacogenomic safety enforcement with hard-stop logic for DPYD/fluoropyrimidines, TPMT/thiopurines, UGT1A1/irinotecan, CYP2D6/tamoxifen, HLA-B*57:01/abacavir, and G6PD/oxidative drugs.
- Hereditary risk governance and cascade detection for BRCA1/2, Lynch syndrome, Li-Fraumeni, TP53, APC, RET, RB1, NF1/NF2, HBB, and SMN1, with automatic family counseling, pedigree reconstruction, and reproductive counseling triggers.
- Sickle-cell-specific genomic adjudication (HBB genotype, beta-S haplotypes, alpha-thalassemia co-inheritance, HPFH status, BCL11A and HBS1L-MYB modifiers, gene therapy eligibility) with explicit rejection of race-essentialist assumptions.

**Methodological innovation**

- Dynamic VUS management: variants of uncertain significance are tracked longitudinally, periodically reclassified, cross-compared against federated cohorts, and escalated as evidence accumulates, rather than remaining epistemically inert.
- Population-aware frequency correction using ancestry-specific reference databases to reduce artificial VUS inflation in African, Indigenous, South Asian, and admixed populations.
- Federated genomic learning through encrypted gradient sharing, enabling evidence accumulation without raw genomic export and supporting ancestry-specific model refinement.

**Key performance indicators**

- VUS resolution rate and time-to-classification
- Pharmacogenomic hard-stop compliance
- Hereditary cascade screening completion
- Actionable variant-to-therapy matching interval
- Cross-institutional interpretation concordance
- Ancestry-specific misclassification reduction

**Integration**

- Upstream: P92 (Liquid Biopsy Surveillance Architect) for longitudinal variant tracking; P105 (Data Sovereignty & Federated Learning Governance) for federated governance.
- Downstream: P102 (Clinical Trial Matching & Eligibility AI) for molecular eligibility; P103 (Real-World Evidence & Digital Twin Generator) for variant-informed prognosis modeling.

## Merits

- Converts genomic interpretation from passive reporting into active clinical intervention infrastructure, classifying variants against ClinGen, OncoKB, CPIC, and pharmacogenomic risk models.
- Blocks unsafe medication orders in genetically vulnerable patients and escalates contraindicated therapies before dispensing.
- Designed to prevent fatal toxicities, including DPYD-associated fluoropyrimidine toxicity, UGT1A1 irinotecan toxicity, G6PD oxidative crises, and other pharmacogenomic dosing catastrophes.
- Identifies hereditary cancer syndromes and automates cascade-detection triggers for at-risk families.
- Ancestry-aware calibration addresses genomic safety gaps in underserved and underrepresented populations.

## Guidance for Use

This document records the design intent and scientific rationale of P91 (Genomic Variant Actionability Arbiter) as published in the CLAI-OS Tier III (Savant Precision Engine, P91–P110) compendium. The executable prompt body is withheld; nothing in this file is sufficient to operate the module. The material is released openly so that the design can be examined, critiqued, and independently validated.

Appropriate use:

- Scientific review, replication design, and methodological critique by researchers and validation groups.
- Reference for integration planning across the P-series registry.
- Citation in scholarly or institutional work describing the CLAI-OS Precision Engine.

Limitations:

- This is not a medical device, a clinical decision-support product, or a standard of care. Nothing in this document may be used to direct diagnosis, treatment, dosing, or triage for any patient.
- Genomic and oncology statements reflect only the claims made in the canonical compendium; publication of this documentation does not constitute independent clinical validation.
- Variant classifications, hard-stop pairs, and syndrome lists above are design specifications drawn from the canonical compendium; they are not a substitute for current ACMG/AMP, CPIC, or institutional guidelines.

---

C0 informational classification; confers no clinical, legal, financial, or safety authority.
